NCT06667960View on ClinicalTrials.gov

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

October 23, 2024

Primary Completion Date

April 1, 2028

Study Completion Date

August 1, 2028

Conditions
Solid Tumor
Interventions
DRUG

JK06

Biparatopic anti-5T4 antibody

Trial Locations (8)

Unknown

RECRUITING

Universitair Ziekenhuis Antwerpen, Antwerp

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

UZ Ghent, Ghent

RECRUITING

CHU UCL Namur - site Godinne, Yvoir

RECRUITING

NEXT Oncology Barcelona, Barcelona

RECRUITING

Vall d Hebron Institute of Oncology VHIO, Barcelona

RECRUITING

Next Oncology Madrid, Madrid

RECRUITING

START Madrid, Madrid

All Listed Sponsors
lead

Salubris Biotherapeutics Inc

INDUSTRY

NCT06667960 - Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter